No connection

Search Results

Stock analysis Score 30 Bullish

Jim Cramer Outlines Tiered Buying Strategy for Oscar Health Stock

Mar 31, 2026 16:36 UTC

Mad Money host Jim Cramer disclosed a phased approach to purchasing shares of Oscar Health, recommending an initial stake now and additional buying if the price climbs to $9. The commentary signals a bullish stance that could influence retail investors and the health‑tech sector.

  • Jim Cramer proposes a phased buying plan for Oscar Health stock.
  • Initial purchase now, followed by a small additional stake.
  • Half of the remaining allocation to be bought at current levels.
  • If the price reaches $9, the final half of the allocation would be purchased at that level.
  • Cramer’s stance may influence retail investors and affect Oscar Health’s market activity.

Jim Cramer, the outspoken host of CNBC’s “Mad Money,” shared a detailed buying plan for Oscar Health during a recent interview. He suggested that investors could begin accumulating the stock immediately, add a modest amount, and then split the remaining allocation between the current price level and a future $9 price point. Cramer’s advice comes at a time when Oscar Health, a technology‑driven health insurer, has been navigating a volatile market environment. While the company’s recent performance metrics were not disclosed, the analyst’s willingness to allocate half of his intended purchase at a higher target underscores confidence in the firm’s longer‑term prospects. The former hedge‑fund manager laid out his step‑by‑step plan: start buying now, acquire a small position, then purchase half of the remaining desired shares at today’s price. If Oscar Health’s share price climbs to $9, he would complete the other half of the allocation at that level. This tiered approach reflects Cramer’s broader strategy of scaling exposure while managing risk. Market participants may take the recommendation as a cue, potentially boosting demand for Oscar Health shares. If investors follow Cramer’s guidance, the stock could see increased liquidity and price support, especially if the $9 target becomes a focal point for market sentiment. The health‑tech sector, already under scrutiny, might also feel ripple effects as attention shifts toward Oscar Health’s valuation trajectory.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Share this article

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Home
Terminal
AI
Markets
Profile